patents keep generics out until around 2031 or 2035, maintaining Novo Nordisks exclusivity and high prices Bookmark CommentsGo to comments Affordable, regulated versions of Ozempic, the well-known diabetes and weight-loss shot from Novo Nordisk, are about to hit markets around the world, which could shake up the obesity drug scene
Specifically, patents for semaglutide are due to expire starting later this month in India, China, Canada, Brazil, and Turkey, along with three other countries later this year, which is expected to spark distribution of generic versions
They also help control blood pressure and make hormones that keep bones strong and blood healthy
But CagriSema's 6-12 month head start, proven semaglutide component, and strong diabetes data position it well for first-mover advantage
They do not have any known negative pharmaceutical interactions